OBJECTIVE:To probe into the effects of Qishenyiqi dripping pills combined with tirofiban hydrochloride on the plasma homocysteine of patients with coronary heart disease.METHODS: 86 patients with coronary heart disease admitted into Hubei Province Hong’an County People’s Hospital from Jul.2014 to Jul.2015 were selected to be divided into observation group and control group via the random number table, with 43 cases in each.The control group were given tirofiban hydrochloride, while the observation group additionally received Qishenyiqi dripping pills based on the control group.RESULTS:The total effective rate of observation group was 93.02%(40/43), significantly higher than that of control group [76.74%(33/43)], the difference was statistically significant(P <0.05).After treatment, the homocysteine level, the heart function indicators, LDL-C, TG and TC in observation group were significantly higher than those of control group, with statistically significant difference(P<0.05).CONCLUSIONS:The efficacy of Qishenyiqi dripping pills combined with tirofiban hydrochloride in treatment of patients with coronary heart disease is significant, which can effectively reduce the level of plasma homocysteine and improve the prognosis of the patients.%目的：探讨芪参益气滴丸联合盐酸替罗非班对冠心病患者同型半胱氨酸水平的影响。方法：选取2014年7月—2015年7月湖北省红安县人民医院收治的冠心病患者86例作为研究对象，以随机数字表法分为观察组和对照组各43例。对照组患者给予盐酸替罗非班。观察组患者在对照组的基础上给予芪参益气滴丸。结果：观察组患者总有效率为93．02％（40／43），明显高于对照组的76．74％（33／43），差异有统计学意义（ P＜0．05）。治疗后，观察组患者同型半胱氨酸水平、心功能指标、低密度脂蛋白胆固醇、三酰甘油、总胆固醇水平均明显优于对照组，差异均有统计学意义（P＜0．05）。结论：芪参益气滴丸联合盐酸替罗非班治疗冠心病，疗效显著，可显著降低患者血清同型半胱氨酸水平，改善预后。
展开▼
